Early detection of myocardial dysfunction in poorly treated pediatric thalassemia children and adolescents: Two Saudi centers experience

Mohamed H. Ibrahim a, c, Ahmed A. Azab b, f, Naglaa M. Kamal c, f, *, Mostafa A. Salama b, f, Soha A. Ebrahim b, Ashraf M. Shahin b, Akram E. El-Sadek b, Waleid E. Abdulghany b, Laila M. Sherief d, Enas A.A. Abdallah c

a Department of Cardiology, Faculty of Medicine, Benha University, Benha, Egypt
b Department of Pediatrics, Faculty of Medicine, Benha University, Benha, Egypt
c Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt
d Department of Pediatrics, Faculty of Medicine, Zagazig University, Zagazig, Egypt
e King Abdulaziz University Hospital, Saudi Arabia
f Elhada Armed Forces Hospital, Saudi Arabia

HIGHLIGHTS

- Cardiac complications are among the most serious complications in Beta Thalassemia Major Patients.
- Tissue Doppler imaging can detect cardiac dysfunction in pediatric thalassemics before development of overt heart disease.
- Patients with normal global functions, by conventional echo, have abnormal ventricular functions detected by TDI.
- TDI is superior to Echo-Doppler in detection of early myocardial damage in asymptomatic thalassaemic patients.

ARTICLE INFO

Article history:
Received 31 January 2016
Received in revised form 15 May 2016
Accepted 16 May 2016

Keywords:
Tissue Doppler imaging
Myocardial dysfunction
Pediatric
Thalassaemia
Echo-Doppler

ABSTRACT

Background & Objective: Cardiac complications are among the most serious complications in Beta Thalassemia Major Patients. Our aim was to evaluate the value of tissue Doppler imaging (TDI) for early detection of myocardial dysfunction in pediatric and adolescent patients with B-TM before development of overt heart failure or cardiomyopathy.

Patients and methods: 100 thalassemic patients below 18 years old and 100 healthy, age & sex matched controls were enrolled in our case-control study. Cases were selected from those attending outpatient clinics and inpatient wards, King Abdulaziz University hospital and Alhada Armed Forces Hospital, Saudi Arabia, between January 2014 and January 2015. They were subjected to echo-Doppler examination for both septal and lateral walls of the basal mitral and tricuspid annuli assessing the systolic myocardial velocity (S wave), early diastolic myocardial velocity (Ea wave) and late diastolic myocardial velocity (Aa wave).

Results: Patients with thalassemia have RV and LV dysfunction on the basis of abnormal TDI derived myocardial velocities. There was a statistically significant differences between patients and controls regarding (Aa) and (S) of the septal wall of the basal mitral annulus and (Ea) of the lateral wall of the mitral annulus. Also patients with thalassemia have significantly higher (S) of the basal tricuspid annulus. These abnormalities were not detected by conventional echo-Doppler.

Conclusion: Clinically asymptomatic thalassemic children and adolescents who had normal global functions by conventional echo-Doppler were found to have abnormal left ventricular and right ventricular dysfunctions detected by TDI. TDI is superior to Echo-Doppler in detection of early myocardial damage in asymptomatic thalassaemic patients.

© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

* Corresponding author. Faculty of Medicine, Cairo University, Cairo, Egypt. E-mail address: nagla.kamal@kasralainy.edu.eg (N.M. Kamal).
1. Introduction

Beta thalassemia major is the most common chronic hemolytic anemia among children and adolescents across the world [1]. Beta-thalassemia is prevalent in Mediterranean countries, the Middle East, including Saudi Arabia, Central Asia, India, Southern China, and the Far East as well as countries along the north coast of Africa and in South America. The highest carrier frequency is reported in Cyprus (14%), Sardinia (10.3%), and Southeast Asia [2–3]. The high prevalence in the Middle East can be attributed the high prevalence (25–60%) of consanguineous marriages [4].

About 1.5% of the global population are carriers of beta thalassemia, with about 60,000 symptomatic individuals born annually. The total annual incidence of symptomatic individuals is estimated at 1 in 100,000 throughout the world [5]. According to Thalassemia International Federation, only about 200,000 patients with thalassemia major are alive and registered as receiving regular treatment [6].

Regular blood transfusion programs and chelation treatment have considerably improved the survival of patients with thalassemia. However, a consequence of chronic transfusion therapy is secondary iron overload, which adversely affect function of the heart, liver and other organs, causing severe morbidity and shorten the life expectancy [11].

Despite improved survival after the use of iron chelators, the cardiac complications are still the primary leading cause of death for young adults with β-thalassemia major [7]. Cardiac dysfunctions in β-thalassemia major have traditionally been attributed to iron-overload [8] related to repeated transfusions and increased intestinal absorption rate combined with a sustained state of increased cardiac output [9].

Cardiac complications, include pericarditis, myocarditis, HF, and arrhythmias [10,11]. However, with proper chelation treatment, pericarditis and myocarditis are now rare [12]. The most common clinical features are dilated cardiomyopathy (with restrictive features) and arrhythmia, primarily atrial fibrillation (AF). In severe cases, ventricular arrhythmias become more common, and ectopic atrial tachycardia, flutter, and chaotic atrial rhythms may also occur.[13].

The age of cardiac death depends primarily on the access to transfusions and chelation. In transfused, but unchelated patients, the typical age at death was 10 years, primarily of cardiac causes [14].

One unit of transfused red blood cells contains approximately 250 mg of iron [15], while the body cannot excrete more than 1 mg of iron per day. A patient who receives 25 units per year, accumulates 5 g of iron per year in the absence of chelation [16].

Although iron chelation therapy can prevent and delay myocardial dysfunction due to the progressive increase of heart iron burden, once dysfunction has become clinically evident it is difficult to reverse [17,18].

Long term control of serum ferritin has been related to protection from cardiac involvement and with improved survival if levels are less than 2500 μg/L [19] with even better outcomes at levels <1000 μg/L [20]. However, serum ferritin is a poor marker of iron balance because ferritin levels change with inflammation/infection, or ascorbate deficiency, and depends on the intensity of blood transfusion, making its reliability uncertain [20].

Detection of early cardiac abnormality is difficult [18,21]. Symptoms and echocardiographic abnormalities arise late in the course of the disease. Usually, patients have normal exercise capacity, with systolic dysfunction occurring in the final stage of disease [21]. Abnormality of longitudinal fiber motion is a sensitive marker of early myocardial dysfunction. Hence, tissue Doppler imaging can be beneficial in the quantitative assessment of regional myocardial function [22,23].

Magnetic resonance imaging (MRI) with the T2* technique is the best method for the detection of tissue iron deposition worldwide. It is noninvasive, and suitable for moving organs like heart [18,24,25]. In children with hemoglobinopathy who received transfusion and chelation, the cardiac T2* was <20 ms only after 10 years of age [26,27]. However, younger onset of cardiac iron, as young as 7 years, has been occasionally reported in TM, especially when poorly chelated [28].

The aim of this study was to investigate the value of using Tissue Doppler Imaging in the detection of non-overt cardiac dysfunction in pediatric and adolescent patients with beta thalassemia major.

2. Patients and methods

We carried a multicenter case-control study on pediatric and adolescent patients of β-TM. Patients were selected from those attending outpatient clinics and inpatient wards, King Abdulaziz University Hospital and Alhada Armed Forces Hospital, Saudi Arabia, between January 2014 and January 2015. It included 100 patients with β-TM aged below 18 years old. Patients were prescribed oral iron chelator; Deferasirox in dose of 20–40 mg/kg. Patients were considered as poorly treated if they were not compliant to their oral iron chelator. We excluded cases with congenital or rheumatic heart disease to exclude structural cardiac disease, including regurgitant valvar lesions, as detected by echocardiography, which may cause ventricular dilatation. We also excluded cases with history of smoking, hypertension, present or past history of overt heart failure. In addition, we excluded other causes of heart failure, other than iron overload, including biochemical causes such as hypercalcemia and thyrotoxicosis. The control group had one hundred age and sex matched apparently healthy individuals with normal cardiovascular status. The study was approved by the research and ethical committees of the contributing hospitals. Written informed consents were obtained from participants or their parents.

All cases and controls were subjected to full history taking (for symptoms of heart failure, co-morbid diseases, drug history and history of transfusions), thorough clinical examination (for signs of heart failure such as gallop rhythm, raised jugular venous pressure and delayed capillary refill), laboratory investigations (CBC and serum ferritin) and imaging using Echo-Doppler and TDI. All echocardiography examinations were done to the patients after receiving blood transfusion as anemia can affect the echocardiographic findings (e.g. marked anemia can cause high cardiac output heart failure).

2.1. Echo-Doppler examination included

(A) M-Mode and two dimensional echo to measure left ventricular end systolic diameter (LVESD), left ventricular end diastolic diameter LVEDD, left ventricular mass (LVM), ejec tion fraction (EF%), fractional shortening (FS%), and tricuspid annular plane systolic excursion (TAPSE).

(B) Conventional Doppler.

(C) Tissue Doppler imaging.

2.2. Echo-Doppler technique

By using ATL 5000 echocardiography machine, tissue Doppler imaging data were acquired transhoracically using a 2.5 or 3.5 MHz transducer. The mitral inflow velocity pattern was recorded in the apical 4-chamber view with the pulsed wave Doppler sample volume positioned at the tip of mitral leaflets during
Table 1
Demographic data of the study patients and control group.

| Parameter              | β-TM     | Control | P-value |
|------------------------|----------|---------|---------|
| Age (Years)            | 12.1 ± 4.1 | 11.5 ± 4.0 | <0.05   |
| Male/female            | 70/30    | 70/30   | <0.05   |
| Weight (kg)            | 35.7 ± 12.7 | 40 ± 10.5 | <0.05   |
| Serum Ferritin (ug/L)  | 2.876 ± 1.189 | 230 ± 22  | 0.000b  |
| Hemoglobin (g/L)       | 91 ± 23  | 115 ± 15 | 0.000b  |

a Significant p value.

Table 2
Conventional echocardiographic data.

| Parameter                  | β-TM     | Control     | P-value |
|----------------------------|----------|-------------|---------|
| LVEDD (cm)                 | 4.4 ± 0.7 | 4 ± 0.52    | 0.000a  |
| LVESD (cm)                 | 2.8 ± 0.5 | 2.6 ± 0.4   | 0.000a  |
| LVM (in gm)                | 108.9 ± 50.4 | 75 ± 20.5 | 0.000b  |
| FS (%)                     | 36.5 ± 6.03 | 35 ± 5.15  | >0.05   |
| EF (%)                     | 66 ± 8.02 | 67 ± 6.5    | >0.05   |
| Mitral E/A ratio           | 2.2 ± 0.8 | 2.3 ± 0.7   | >0.05   |
| TAPSE (cm)                 | 2.41 ± 0.42 | 2.24 ± 0.36 | >0.05   |

a Significant p value, LVEDD: left ventricular end diastolic diameter, LVESD: left ventricular end systolic diameter, LVM left ventricular mass, FS fractional shortening, E/A ratio: the ratio of the early (E) to late (A) ventricular filling velocities, TAPSE: tricuspid annular plane excursion.
We found that the LV EF, FS, and TAPSE, in thalassemic patients were comparable to those of the control group. This was suggestive of preserved systolic function, as assessed by conventional echocardiography.

These results are similar to other reports which also demonstrated preserved left ventricular systolic function in spite of cardiac dilatation with no significant difference between the studied cases and controls as regards the mean values of EF and FS [35,39–41]. However, other studies reported a significantly lower LVEF in thalassemia patients in comparison with healthy age and sex-matched individuals [42,43]. However, the mean values of EF in these studies were more than 55% in the studied thalassemia patients.

Compared with controls, the diastolic indices of LV in beta thalassemia patients (trans-mitral E/A ratio) showed no significant difference between cases and controls which indicates preserved global diastolic function of the LV. This is consistent with reports from other studies [36,43,44]. Absence of a significant difference in E/A ratio in thalassemic patients in comparison to the control subjects could be explained by the exclusion of patients with heart failure symptoms. It could be declared that the E/A ratio alone is not enough to diagnose diastolic dysfunction [45].

On the contrary, other investigators found diastolic dysfunction of restrictive pattern with increased E/A ratio in patients with beta-thalassemia compared to the control group [17,46]. It has been assumed that myocardial iron deposition in some thalassemic patients may not directly affect left ventricular systolic function, but it may rather cause diastolic dysfunction with left ventricular myocardial performance index.

Tissue Doppler Imaging (TDI) is a relatively new Doppler ultrasound modality that records regional systolic and diastolic velocities within the myocardium. It allows quantitative measurement of both systolic and diastolic velocities directly from the ventricular myocardium with the determination of the extent of mitral annular displacement in systole and diastole [52].

This new technique can show additional information compared with other echocardiography techniques, detecting even minor changes before the occurrence of abnormal indices of global ventricular dysfunction [45].

In our study assessment of the mitral valve with pulsed Doppler tissue imaging showed statistically significant differences between the patients, with no overt cardiac clinical impairment, and the control subjects in late diastolic myocardial velocities (Aa) and systolic myocardial velocities (S) at the basal mitral annulus of the septal wall. Additionally, patients with thalassemia have significantly higher early diastolic myocardial velocities (Ea), at the basal mitral annulus of the lateral wall, than controls.

In accordance with these findings, other authors had reported significant lower tissue Doppler systolic velocity in the β-TM group compared to controls [42,45]. On the contrary, Larussi et al. [44] found that all Doppler tissue imaging systolic and diastolic parameters of the mitral annulus were similar in patients with beta thalassemia major before and after transfusion to those of healthy subjects. Nevertheless, significantly lower early diastolic velocity was reported by some investigators [42,45,53]. These conflicting results might be due to different age of the studied groups, as it is known that age and body surface area are the most important factors affecting isovolumic relaxation and deceleration times [54].

Iron loading of the heart can be patchy, mainly affecting the ventricles with deposition predominantly in the septum with other areas of the ventricles and heart being affected later in the disease process and these can explain the index findings [55].

An interesting finding, albeit not that accurate like cardiac catheterization, is that pulmonary capillary wedge pressure (PCWP) estimated by echo-Doppler was higher in the thalassemia patients than in the control group which correlates with higher left ventricular end-diastolic pressure and left ventricular dysfunction. This result coincides with the result of another study which stated increased PCWP in thalassemia patients as compared to iron deficiency anemia and healthy control groups [56]. Similarly, they correlated this finding with left atrial volume that was found significantly higher in the thalassemia patients than control group.

We found that Septal E/Ea ratio was significantly higher in thalassemia patients when compared with controls. This was in agreement with authors [57], who found that there was a significant elevation in E/E’ in the TM patients compared to the control group. On the contrary this difference was not significant in the other studies [36,53]. The difference from our findings can be explained by enrollment of different age groups, difference in iron load, or different compliance to chelation therapy.

The E/Ea ratio has a special diagnostic importance for diastolic dysfunction among thalassemic patients due to its load independent nature, its unaffection by elevated LA pressure and linear correlation with LV end diastolic pressure [57,58].

Assessment of the tricuspid valve showed significant difference in only systolic myocardial velocity (S) at the basal tricuspid annulus by tissue Doppler imaging. These alterations in myocardial velocities by TDI might indicate earlier left and right ventricular dysfunction.

Larussi et al. [44] found that lateral tricuspid annulus velocities in the beta thalassemia patients before transfusion was significantly reduced than controls. More recently, Abdelmoktader and Azer, found comparable (S) wave velocity at lateral margin of the tricuspid annulus in thalassemic patients when compared to control group [42].

The myocardial performance index (Tei index) of LV of patients was significantly higher than control group. The impaired Tei index

| Table 3                                                                 |
|-------------------|----------------|---------------|
| Parameter         | β-TM            | Control       |
|                   | P-value         |               |
| Mitral valve, septal wall |                |               |
| Ea (cm/s)         | 12.7 ± 2.10     | 13.2 ± 2.41   | >0.05         |
| Aa (cm/s)         | 7.70 ± 2.50     | 5.72 ± 1.41   | 0.000         |
| S (cm/s)          | 10.70 ± 1.75    | 7.90 ± 1.23   | 0.000         |
| Septal E/Ea ratio | 8.10 ± 1.31     | 6.55 ± 1.60   | 0.000         |
| PCWP              | 11.9 ± 1.6      | 10.0 ± 1.95   | 0.000         |
| Mitral valve, lateral wall |            |               |
| Ea (cm/s)         | 18.2 ± 2.41     | 15.8 ± 1.82   | 0.000         |
| Aa (cm/s)         | 7.30 ± 1.41     | 6.60 ± 1.72   | >0.05         |
| S (cm/s)          | 10.3 ± 2.30     | 9.61 ± 1.80   | >0.05         |
| LV Tei index      | 0.32 ± 0.11     | 0.41 ± 0.10   | 0.000         |
| Tricuspid valve   |                |               |
| S (cm/s)          | 14.8 ± 2.63     | 12.6 ± 1.30   | >0.05         |
| Ea (cm/s)         | 15.3 ± 2.24     | 13.8 ± 3.00   | >0.05         |
| Aa (cm/s)         | 10.4 ± 2.54     | 8.83 ± 2.74   | >0.05         |
| RV Tei index      | 0.24 ± 0.09     | 0.18 ± 0.08   | >0.05         |

* Significant p value, Ea: early diastolic myocardial velocity, Aa: late diastolic myocardial velocity, S: systolic myocardial velocity, E: early diastolic myocardial velocity of the mitral annulus, LV Tei: left ventricle myocardial performance index, RV Tei: right ventricle myocardial performance index.
as detected by TDI in patients with normal conventional echocardiographic parameters, particularly EF, supports the idea that TDI can be an early sensitive indicator of cardiac dysfunction in asymptomatic beta-TM. This finding was in agreement with the report of authors who studied 55 asymptomatic beta-thalassemia patients with median age of 20 years [59].

Hence, among our patients, with beta thalassemia, and asymptomatic cardiac dysfunction showing preserved global systolic function as detected by conventional echocardiography, tissue Doppler imaging technique has shown latent systolic and diastolic cardiac dysfunction. This denotes the importance of this modality for evaluation of beta thalassemia children and adolescents to detect asymptomatic cardiac dysfunction before being detected by conventional echocardiography. This is particularly important in developing countries where the Magnetic Resonance Imaging (MRI T2*), the gold standard diagnostic modality of early detection of iron cardiac load, is still not convenient for mass screening due to its cost and limited availability.

6. Limitations

The small number of patients and non-availability of the more recent modalities of TDI like strain, strain rate, and speckle tracking were the major limitations of our study. These modalities can display intrinsic cardiac deformation and is superior to TDI due to its independence of cardiac translational motion and tethering effect of the adjacent segments. Another limitation is that the use of T2-weighted MRI as a diagnostic marker of body iron load was beyond the scope of our study. Our study was based on the echocardiographic parameters. Future studies can be conducted using cardiac catheterization and correlating the findings with the echocardiographic parameters.

7. Conclusion

Tissue Doppler imaging is superior to conventional echocardiography in giving an early evidence of systolic and diastolic myocardial dysfunction in non-symptomatic thalassemic patients. Hence, TDI can be applied as an integrated part of assessment of children and adolescents with beta-thalassemia.

Ethical approval

The study was approved by the research and ethical committees of the contributing hospitals.

Funding

No funds were provided to the current work.

Author contribution

Mohamed H. Ibrahim, Naglaa M. Kamal, Enas A.A. Abdallah:

- Substantial contributions to the conception and design of the work.
- Drafting the work and revising it critically for important intellectual content.
- Final approval of the version published.
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Mostafa A Salama, Soha A Ebrahim, Ahmad A Azab:

- Acquisition, analysis, and interpretation of data.
- Drafting the work.
- Final approval of the version published.
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ashraf M. Shahin, Akram E El-Sadek:

- Acquisition, analysis, and interpretation of data.
- Reworking the work critically for important intellectual content.
- Final approval of the version published.
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Waleid E Abdulghani, Laila M Sherief:

- Acquisition, analysis, and interpretation of data.
- Drafting the work.
- Final approval of the version published.
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conflicts of interest

Authors declare no conflicts of interest.

Guarantor

Naglaa M Kamal (the corresponding author).
Associate Professor of pediatrics, Faculty of Medicine, Cairo University, Egypt.

References

[1] E. Cassinerio, A. Roghi, P. Pedrotti, et al., Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients, Ann. Hematol. 91 (9) (2012 Sep) 1443–1449.
[2] M.A. el-Hazmi, A.S. Wasy, Appraisal of sickle-cell and thalassaemia genes in Saudi Arabia, East Mediterr. Health J. 5 (1999) 1147–1153.
[3] J. Flint, R.M. Harding, A.J. Boyce, J.B. Clegg, The population genetics of the hemoglobinopathies, Bailliere’s Clin. Hematol. 11 (1998) 1–50.
[4] M. Saff, N. Howard, Exploring the effectiveness of mandatory premartial screening and genetic counselling programmes for β-thalassaemia in the Middle East: a scoping review, Public Health Genomics 18 (4) (2015) 193–203, http://dx.doi.org/10.1159/000430837, Epub 2015 May 29.
[5] E.P. Vichiński, Changing patterns of thalassemia worldwide, Ann. N. Y. Acad. Sci. 1054 (2005) 18–24.
[6] Thalassemia International Federation, Guidelines for the Clinical Management of Thalassemia, second ed., 2008.
[7] J.M. Walker, The heart in thalassemia, Eur. Heart J. 2 (2002) 102–105.
[8] S.V. Brili, A.I. Tzonou, S.S. Castelanos, C.J. Aggeli, C.A. Tentolouris, C.E. Pitsavos, P.K. Toutouzas, The effect of iron overload in the hearts of patients with beta-thalassemia, Clin. Cardiol. 20 (6) (1997 Jun) 541–546.
[9] E. Stoyanova, C. Cloutier, H. Feltly, W. Lemsaddek, N. Ah-Son, M. Trudel, Evidence for a novel mechanism independent of myocardial iron in β thalassemia cardiac pathogenesis, PLoS One 7 (12) (2012) e52128.
[10] M.A. Engle, M. Erlandson, C.H. Smith, Late cardiac complications of chronic, severe, refractory anaemia with hemochromatosis, Circulation 30 (1964) 698–705.
[11] L.M. Buja, W.C. Roberts, Iron in the heart: etiology and clinical significance, Am. J. Med. 51 (1971) 209–221.
[12] D.J. Pennell, J.E. Udelson, A.E. Arai, B. Bozkurt, A.R. Cohen, R. Galanello, et al., on behalf of the American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging, Cardiovascular function and treatment in [I-
